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In	chronic	viral	infections,	CD8+	T	cells	become	functionally	deficient	and	display	multiple	molecular	altera-
tions.	In	contrast,	only	little	is	known	of	self-	and	tumor-specific	CD8+	T	cells	from	mice	and	humans.	Here	we	
determined	molecular	profiles	of	tumor-specific	CD8+	T	cells	from	melanoma	patients.	In	peripheral	blood	
from	patients	vaccinated	with	CpG	and	the	melanoma	antigen	Melan-A/MART-1	peptide,	we	found	func-
tional	effector	T	cell	populations,	with	only	small	but	nevertheless	significant	differences	in	T	cells	specific	
for	persistent	herpesviruses	(EBV	and	CMV).	In	contrast,	Melan-A/MART-1–specific	T	cells	isolated	from	
metastases	from	patients	with	melanoma	expressed	a	large	variety	of	genes	associated	with	T	cell	exhaustion.	
The	identified	exhaustion	profile	revealed	extended	molecular	alterations.	Our	data	demonstrate	a	remark-
able	coexistence	of	effector	cells	in	circulation	and	exhausted	cells	in	the	tumor	environment.	Functional	T	cell	
impairment	is	mediated	by	inhibitory	receptors	and	further	molecular	pathways,	which	represent	potential	
targets	for	cancer	therapy.
Introduction
CD8+ T cell responses in acute viral diseases have been extensively 
characterized in mice and humans (1–6). While viruses multiply 
rapidly during the first week of infection, CD8+ T cells become 
activated and expand vigorously, reaching a peak of T cell effec-
tor function. In parallel with the consequent decline of viral anti-
gen, the majority of CD8+ T cells undergo apoptosis (contrac-
tion phase). After pathogen clearance, memory T cells persist for 
years at low frequencies, ready for accelerated protective immune 
responses in case of reinfection.
When pathogens are not eliminated, T cells may persist in much 
larger numbers. They are composed of large numbers of effector 
cells and low percentages of memory cells. Essentially, there are 2 
scenarios of long-term CD8+ T cell activity in viral infection: the 
first scenario is observed, e.g., in persistent herpesvirus infection 
(e.g., EBV, CMV) in healthy individuals, where T cells successfully 
contain the viruses and thus are protective even though they do 
not eliminate the viruses entirely. The second scenario is associat-
ed with viral spread and progressive tissue damage in the presence 
of large numbers of CD8+ T cells, e.g., in HIV-1, HBV, or HCV infec-
tion, and in the murine model of lymphocytic choriomeningitis 
virus clone 13 (LCMV clone 13) infection. These 2 scenarios are 
distinguished by a fundamentally different functional competence 
of CD8+ T cells. In the first scenario, such as in healthy donors 
infected with EBV or CMV, viral antigen-specific T cells are func-
tionally competent and thus ready for immediate cytokine pro-
duction and cytotoxicity (7). These cells contribute to rapid reduc-
tion of viral load and restoration of health by viral containment to 
small anatomical compartments (8–10). In contrast, CD8+ T cells 
in the second scenario (i.e., the failure of viral containment) are 
functionally impaired (11, 12). The murine infection with LCMV 
clone 13 is a prototype model of functional T cell impairment, 
called T cell exhaustion, with progressively reduced production of 
IL-2, TNF-α, and IFN-γ, followed by incapacity to lyse (infected) 
target cells (13, 14). Analysis of such cells has led to significant 
discoveries, such as the identification of PD-1, a major inhibitory 
receptor involved in T cell function (15). Gene expression profil-
ing of murine T cells allowed a global assessment, revealing that 
T cell exhaustion is associated with numerous molecular altera-
tions, affecting genes regulating chemotaxis, adhesion, corecep-
tors, migration, metabolism, and energy (2). Hereafter, we call 
these multiple changes exhaustion profile.
In humans, functional deficits were found in HIV-1–, HCV-, 
and HBV-specific CD8+ T cells (11, 16, 17), and a recent gene 
expression study described an exhaustion profile in HIV-1 
patients (18). In contrast to virus-specific T cells, only little is 
known of self- and tumor-specific CD8+ T cells. In humans and 
mice, it remains to be determined whether functional impair-
ments of bona fide self-antigen–specific T cells represent 
exhaustion, anergy, or other functional states. In melanoma 
patients, there are substantial numbers of long-term persist-
ing effector-memory CD8+ T cells, despite failures of immune 
protection from disease. Circulating human tumor-specific 
CD8+ T cells may be cytotoxic and produce cytokines in vivo 
(19–21), indicating that self- and tumor-specific human CD8+ 
T cells can reach functional competence after potent immuno-
therapy such as vaccination with peptide, incomplete Freund’s 
adjuvant (IFA), and CpG (19) or after adoptive transfer (22). In 
contrast to peripheral blood, T cells from metastasis are func-
tionally deficient, with abnormally low cytokine production 
and upregulation of the inhibitory receptors PD-1, CTLA-4, and 
TIM-3 (20, 23–25). Functional deficiency is reversible, since T 
cells isolated from melanoma tissue can restore IFN-γ produc-
tion after short-term in vitro culture (20). However, it remains 
to be determined whether this functional impairment involves 
Conflict	of	interest: The authors have declared that no conflict of interest exists.
Citation	for	this	article: J Clin Invest. 2011;121(6):2350–2360. doi:10.1172/JCI46102.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 121   Number 6   June 2011 2351
further molecular pathways, possibly resembling T cell exhaus-
tion or anergy as defined in animal models (2, 26).
The identification of mechanisms responsible for functional 
impairment of self- and tumor-specific T cells may reveal targets 
for novel cancer therapies. Human CD8+ T cell responses specific 
for the melanoma antigen Melan-A/MART-1 represent a model 
wherein self-specific T cells can be studied in great detail. Fur-
thermore, we took advantage of the strong immunogenicity of 
vaccination with peptide plus CpG (19). By direct ex vivo analysis, 
we compared Melan-A/MART-1–specific T cells (hereafter called 
tumor-specific T cells) with virus-specific T cells by microarray 
analysis, quantitative PCR (qPCR), and flow cytometry. Recent 
studies focused on circulating T cells (27), whereas T cells resid-
ing in tumor tissue remain poorly characterized. Therefore, we 
isolated T cells from both peripheral blood and metastases. We 
found that the former show molecular and functional features 
of effector cells, similar to circulating CMV-specific T cells, dem-
onstrating that human self- and tumor-specific T cells have the 
potential to become competent effector cells. In marked con-
trast, the tumor-specific T cells isolated from metastatic tissue 
displayed an exhaustion profile, consisting of large numbers of 
molecular alterations.
Results
Naive and virus-specific T cells show no significant differences between mela-
noma patients and healthy donors. Recently we demonstrated reproduc-
ibility of gene expression profiling of small numbers of (1,000) T 
cells (28). Applying this technique (Supplemental Figure 1, A–D; 
supplemental material available online with this article; doi:10.1172/
JCI46102DS1), we analyzed naive and antigen-specific T cells upon 
sorting of PBMC subsets by flow cytometry. We compared gene 
expression profiles of naive CD8+ T cells from melanoma patients 
and healthy donors and found no significant differences (Figure 1A), 
confirming previous studies (29). For the isolation of antigen-spe-
cific cells, we used tetramers and sorted T cells specific for the tumor 
antigen Melan-A/MART-1, the EBV antigen BMLF1, and the CMV 
antigen pp65. We compared EBV-specific T cells between healthy 
donors and patients and did not observe significant differences in 
gene expression (Figure 1B). In parallel, we found similar pheno-
types and similar IFN-γ production (Figure 1, C and D). Thus, many 
CD8+ T cells appeared relatively normal in our patients.
Gene expression profiling of naive versus nonnaive T cells. Before ana-
lyzing tumor-specific T cells, we validated our approach using 
only 1,000 cells, by searching for the known molecular differences 
between naive and nonnaive CD8+ T cells (28, 30). We selected 
genes showing a 3-fold or greater change between naive and nonna-
ive CD8+ T cells, plus a P value adjusted for the false discovery rate 
(FDR) of less than 0.05 (Supplemental Figure 2A). With this strat-
egy, we identified 409 upregulated and 364 downregulated genes 
in naive relative to nonnaive CD8+ T cells (Supplemental Table 1) 
and found that all naive T cell populations clustered together and 
apart from all nonnaive T cells (Figure 2A). We selected 8 genes 
for verification by qPCR. Without exception, they confirmed the 
microarray results, whereby qPCR detected quantitatively larger 
differences, owing to the higher sensitivity of qPCR (Supplemental 
Figure 2B). Additionally, the data for many of the differentially 
expressed genes (e.g., CCR7, LEF1, SELL, IFNG, GZMB, and HLADR; 
Supplemental Figure 2C) confirmed well-known differences 
between naive and nonnaive T cells.
We assessed biological classification of the 773 differentially 
expressed genes by assigning them to 9 Gene Ontology (GO) terms 
and then determined whether any of these GO terms were overrepre-
sented in our list compared with the predicted frequency in a random 
gene list. Not surprisingly, we found about twice as many immune 
response genes as the number predicted from a random gene test 
(Figure 2B). Additionally, the GO terms for translation, cell death, 
and apoptosis were overrepresented in nonnaive cells, whereas genes 
involved in DNA repair were underrepresented.
In 2005, Willinger et al. made a thorough gene expression 
analysis of human CD8+ T cells from healthy donors without 
distinction of antigen specificity (31). They determined large dif-
ferences between naive and total effector cells, providing gene 
Figure 1
Naive and virus-specific T cells show no significant 
differences between melanoma patients and healthy 
donors. (A and B) Volcano plots for all gene probes 
on the microarray, showing expression differences and 
P values of naive T cells (healthy donors [HDs] versus 
patients; A) or EBV-specific T cells (healthy donors 
versus patients; B). Each point represents 1 gene 
probe. (C) Lymphocytes were stained with an A2/EBV 
BMLF1280–288 tetramer together with anti-CD8, anti-
CD45RA, and anti-CCR7. The inset shows a dot plot 
distinguishing the phenotypes among total CD8+ T cells 
analyzed as controls: naive (N) (CD45RA+CCR7+), cen-
tral memory (CM) (CD45RA–CCR7+), effector memory 
(EM) (CD45RA–CCR7–) and effector memory RA+ cells 
(EMRA) (CD45RA+CCR7–). Bar graph depicts the per-
centage (mean ± SD) of each phenotype of total CD8+ 
cells or total EBV tetramer-positive populations from 
healthy donors or patients. (D) IFN-γ production by 
EBV-specific T cells upon 4-hour stimulation. Whiskers 
in box plots indicate maximum and minimum values 
measured. Cross indicates the mean, while line indi-
cates the median.
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sets characteristic for the distinction of the 2 populations. From 
these data, we used 2 gene sets, one which is up- and one which 
is downregulated in effector CD8+ T cells. Furthermore, in 2007, 
Wherry et al. defined gene sets that were up- or downregulated 
in antigen-specific memory, effector, and exhausted CD8+ T cells 
from LCMV-infected mice (2). While the gene sets from Willinger 
et al. described long-term effects of effector differentiation (analy-
sis of total human CD8+ T cell subsets in steady state), the gene 
sets from Wherry et al. described shorter-term changes of gene 
expression (model of acute and chronic infection). With Gene Set 
Enrichment Analysis (GSEA), we determined whether gene sets 
were enriched in our rank-ordered list of differentially expressed 
genes. Our naive T cells showed upregulation of the 2 gene sets 
downregulated in effector cells as identified by Wherry et al. (ref. 2 
and Figure 2C) and by Willinger et al. (ref. 31 and Figure 2C). Con-
versely, the gene sets enriched in our nonnaive T cells were those 
upregulated in effector cells as defined by Wherry et al. (Figure 2D) 
and by Willinger et al. (Figure 2D). Together, these data confirm 
the reproducibility of microarray analysis of highly purified cells, 
validating our approach of ex vivo analysis of antigen-specific T 
cells with small cell numbers.
Different gene expression profiles between circulating tumor- and virus-
specific T cells. A major aim of our study was to determine whether 
tumor-specific CD8+ T cells were similar to or different from virus-
specific T cells. By applying the same selection criteria as above 
(i.e., fold change ≥ 3, adjusted P < 0.05), we found 390 genes that 
were differentially expressed between tumor- and EBV-specific T 
cells (259 upregulated and 131 downregulated) (Figure 3A and 
Supplemental Table 2), while only 184 genes (72 upregulated and 
112 downregulated) were differentially expressed when compared 
with CMV-specific T cells (Figure 3B and Supplemental Table 3). 
Therefore, the differences between CMV- and tumor-specific T 
cells were smaller than between EBV- and tumor-specific T cells. 
A 2-way hierarchical clustering with these probes showed clear 
distinction between tumor- and EBV-specific (Figure 3C) and 
tumor- and CMV-specific T cell populations (Figure 3D) from the 
individual patients and healthy donors despite the high genetic 
heterogeneity between individuals and the similarity of surface 
markers of these T cell populations (Supplemental Figure 3A). 
Microarray data were confirmed through the analysis of a series 
of genes by qPCR, among them several inhibitory receptors 
(Figure 3, E and G). As compared with both EBV- and CMV-specific 
cells, TIM3 and CTLA4 were upregulated in tumor-specific T cells, 
while CD160 was upregulated in virus-specific T cells (Figure 3, 
E and G). 2B4 was upregulated in CMV-specific T cells. Interest-
ingly, as compared with EBV-specific T cells, tumor-specific T 
cells expressed more mRNA encoding granzyme B (GZMB) and 
granulysin (GNLY), but less XCL1 (lymphotactin). XCL1 was also 
upregulated in CMV-specific T cells. Finally, we performed a GO 
term analysis and found that the differences between tumor- and 
the 2 virus-specific T cell populations were smaller (Figure 3, 
F and H) than the differences of naive versus nonnaive T cells 
Figure 2
Gene expression of naive and effector T cells from peripheral blood. (A) Two-way hierarchical clustering based on the identified 773 genes, 
separating all naive from nonnaive T cells. Red indicates overexpression and blue underexpression relative to the mean. Each row represents 
1 gene and each column 1 1,000-cell sample from 1 patient or healthy donor. (B) Relative overexpression of GO terms associated with the identi-
fied genes, calculated as described in Methods. (C and D) GSEA of publicly available gene sets describing naive and effector T cells. Positions 
of selected example genes are indicated. Gene sets comprise genes enriched in naive T cells (C) or in effector cells (D). Genes to the left and 
right of the rank-ordered list are enriched in naive T cells and nonnaive T cells, respectively.
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(Figure 2B). Remarkably, immune response genes were not spe-
cifically overrepresented relative to a random gene list, suggesting 
overall similar expression of immune genes in effector T cells spe-
cific for EBV, CMV, and Melan-A/MART-1, despite the differences 
found for inhibitory receptors.
The gene expression profile of circulating tumor-specific CD8+ T cells 
corresponds to late-differentiated effector cells. EBV- and CMV-specific 
T cells are recognized as prototypes of early- and late-differenti-
ated effector cells, respectively (7). This distinction fits with the 
phenotypes of these 2 populations (Supplemental Figure 3A). We 
created rank-ordered gene lists to compare tumor-specific with the 
2 virus-specific CD8+ T cell populations. The gene sets defined as 
upregulated in effector cells by Wherry et al. (ref. 2 and Figure 4A) 
and Willinger et al. (ref. 31 and Figure 4A) were enriched in tumor-
specific cells, as compared with their EBV-specific counterparts. In 
contrast, the only gene set enriched in EBV-specific T cells com-
pared with tumor-specific T cells was the small gene set contain-
ing genes specifically upregulated in memory cells when compared 
with naive CD8+ T cells as defined by Wherry et al. (Figure 4B). 
This is likely due to the lower degree of effector differentiation of 
EBV-specific T cells (which are nevertheless predominantly effector 
rather than memory cells; Supplemental Figure 3A). When we com-
pared tumor- with CMV-specific CD8+ T cells, we could not find 
enrichment for any gene set (Figure 4C), confirming the late dif-
ferentiation stage of tumor-specific T cells. To verify the differential 
expression of granzyme B and perforin ex vivo on the protein level, 
we performed intracellular staining. As expected, the tumor- and 
CMV-specific CD8+ T cells expressed more granzyme B and perforin 
than the EBV-specific CD8+ T cells (Figure 4D). However, all 3 anti-
gen-experienced T cells produced high levels of IFN-γ after 4 hours 
Figure 3
Gene expression of circulating CD8+ T cells depending on antigen specificity. (A and B) Volcano plots for all gene probes, showing differential 
expression and P values of the comparison of tumor- versus EBV-specific T cells (A) or tumor- versus CMV-specific T cells (B); diagramming 
is similar to that in Figure 1. (C and D) Two-way hierarchical clustering based on the identified gene probes separating all tumor-specific T cells 
from EBV- (C, 405 gene probes corresponding to 390 genes) and from CMV-specific T cells (D, 187 gene probes corresponding to 184 genes). 
Red indicates overexpression and blue underexpression relative to the mean. Each row represents 1 gene and each column 1 1,000-cell sample 
from 1 patient (tumor-, EBV- and CMV-specific cells) or healthy donor (EBV-specific cells, n = 4). (E and G) Log fold changes between tumor- and 
EBV- (E) or tumor- and CMV-specific T cells (G) of data from microarrays (blue bars) and qPCR (red bars). Positive and negative values indicate 
overexpression in tumor- and in virus-specific T cells, respectively. Data are represented as mean ± SEM. (F and H) Relative overexpression of 
GO terms associated with the identified 390 genes (Melan-A/MART-1 versus EBV; F) or with the identified 184 genes (Melan-A/MART-1 versus 
CMV; H), calculated as described in Methods.
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triggering with peptide-loaded T2 cells (Supplemental Figure 3B). 
Together, our results demonstrate that tumor- and CMV-specific 
CD8+ T cells resembled each other closely, while EBV-specific CD8+ 
T cells were in earlier stages of effector differentiation.
In contrast to circulating T cells, tumor-specific T cells from tumor-infiltrated 
lymph nodes show an exhaustion profile. Previous studies indicated that 
functional impairment of tumor-specific T cells may occur primari-
ly in situ (20, 24), which was also the case after strong systemic T cell 
activation by CpG-based vaccination (25). Therefore, we established 
a clinical investigation protocol to recover large numbers of live cells 
from tumor-infiltrated lymph nodes (TILN). This enabled us to per-
form functional studies and gene expression analysis ex vivo from 
tumor-specific T cells from TILN, in comparison with circulating T 
cells. Tumor-specific T cells from metastases showed highly insuffi-
cient IFN-γ production upon 4-hour peptide triggering (Figure 5A), 
as published previously (20, 24). Microarray analysis allowed the 
identification of 332 genes (201 up- and 131 downregulated in 
TILN; Supplemental Table 4) that were differentially expressed 
between tumor-specific CD8+ T cells from PBMC versus TILN, 
using the same criteria as before (Figure 5B). Hierarchical cluster-
ing using these genes divided the 13 samples into 2 groups only, 
one for blood and the other for TILN-derived tumor-specific T cells 
(Figure 5C). qPCR performed for a selection of genes allowed proper 
validation (Figure 5D). Among the genes upregulated in tumor-
specific cells from TILN were the lymph node retention receptor 
CRTAM, the chemokines XCL1 and XCL2, the activation marker 
TNFRSF9, and the inhibitory receptor CTLA4. CXCL13, a B cell 
chemoattractant usually found in the B cell compartment of lymph 
nodes, was one of the most highly overexpressed genes. Among the 
genes downregulated in TILN cells were the cell-growth–regulating 
protein LYAR and the inhibitory receptor KLRG1. When classifying 
the differentially expressed genes into broad GO terms, we found 
that genes involved in cell death and apoptosis and in the immune 
response were overrepresented compared with a randomly selected 
gene list (Figure 5E). To obtain a more general overview of the dif-
ferences of tumor-specific CD8+ T cells from blood versus TILN, 
we studied gene sets specific for effector cells, naive cells, memory 
cells, and exhausted cells, as described above. Remarkably, the gene 
set described for exhausted T cells (2) was significantly enriched in 
tumor-specific cells from TILN, in contrast with the gene sets char-
acteristic for naive, memory, and effector T cells (Figure 5F). These 
large-scale data demonstrate an impressive exhaustion profile, with 
extended molecular alterations of multiple pathways in tumor-spe-
cific CD8+ T cells from metastases.
Figure 4
Circulating tumor-specific T cells are late-differentiated effector cells, resembling CMV-specific T cells. (A) Gene set enrichment of genes 
describing effector cells (see Figure 2D). Genes to the left and right of the rank-ordered list are enriched in tumor- and EBV-specific T cells, 
respectively. (B) Gene set enrichment of genes describing memory cells (2). Genes to the left and right of the rank-ordered list are enriched in 
tumor- and EBV-specific T cells, respectively. (C) No differences were found between Melan-A/MART-1– and CMV-specific T cells, demon-
strated by a gene set defining effector cell–related genes (31). (D) Intracellular staining of naive and antigen-specific T cells. Top panels show 1 
representative example; below are the combined results of all samples (EBV and CMV, n = 5; Melan-A, n = 15; naive, n = 25). Data of EBV- and 
CMV-specific T cells are from healthy donors, while data of tumor-specific T cells are from patients. ***P < 0.001. Whiskers in box plots indicate 
maximum and minimum values measured. Line indicates the median.
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Enhanced expression of inhibitory receptors, such as CTLA4 and 
LAG3, was observed in T cell exhaustion (2, 23, 32–34). Interest-
ingly, their expression was enriched in TILN cells, with the notable 
exceptions of PTGER2 and KLRG1 (Figure 5F). However, KLRG1 was 
described as more strongly expressed in functionally competent 
effector cells than in exhausted T cells (2), compatible with our data. 
The absolute expression values of selected inhibitory receptors are 
detailed in Table 1. Although it seems likely that the tumor micro-
environment plays a role, the reasons for the observed enhanced 
expression of inhibitory receptors remain to be elucidated.
Differential protein expression of multiple inhibitory receptors by tumor- 
and virus-specific CD8+ T cells. To determine expression of inhibitory 
receptors at the protein level, we produced tetramers labeled with 
(multiple) different fluorochromes and used them in combina-
tion with several monoclonal antibodies (multi-tetramer staining; 
Figure 6A). Compatible with mRNA data, CD160 and 2B4 were more 
frequently expressed by both EBV- and CMV-specific T cells than by 
tumor-specific T cells from peripheral blood (Figure 6B), in agree-
ment with a study reporting that most CD160+ cells coexpressed 
2B4 (35). In contrast, circulating tumor-specific T cells expressed 
more TIM-3 and more PD-1 than the 2 virus-specific T cell popu-
lations (Figure 6B), in line with 2 recent reports of TIM-3+PD-1+ 
cells among tumor-specific T cells (23, 36). Large percentages of 
PD-1+ tumor-specific T cells coexpressed TIM-3 and/or KLRG-1. 
Similar results were obtained when we analyzed the mean fluores-
cence intensity (Supplemental Figure 4). Our technique allowed 
analyzing simultaneous coexpression of multiple inhibitory recep-
tors, for CD160, KLRG-1, PD-1, and TIM-3, or for 2B4, LAG-3, and 
CTLA-4. We found a pronounced increase in inhibitory receptor 
coexpression from naive to central memory, effector memory, and 
effector memory RA+ cells (data not shown). On antigen-specific 
T cells, there were various combinations of inhibitory receptors. 
Melan-A–specific T cells from TILN expressed more CTLA-4, 
LAG-3, and TIM-3, but less KRLG-1 than their counterparts from 
Figure 5
Exhaustion profile of tumor-specific T cells in situ. (A) IFN-γ production by tumor-specific T cells from the circulation (blood; n = 6) or TILN (n = 8) 
after 4-hour antigen stimulation. Whiskers in box plots indicate maximum and minimum values measured. Cross indicates the mean, while line 
indicates the median. **P < 0.01. (B) Differential gene expression by tumor-specific T cells isolated from blood versus TILN, as illustrated by 
a volcano plot for all gene probes. (C) Two-way hierarchical clustering based on the identified 346 genes separating all blood-derived tumor-
specific T cells from their TILN counterparts. Red indicates overexpression and blue underexpression relative to the mean. Each row represents 
1 gene and each column 1 1,000-cell sample from 1 patient. (D) Log fold change between tumor-specific T cells from blood versus TILN; data 
from microarrays (blue bars) and qPCR (red bars). Positive and negative values indicate overexpression in tumor-specific T cells from TILN and 
from blood, respectively. Mean ± SEM. (E) Relative overexpression of GO terms associated with the identified genes, calculated as described in 
Methods. (F) Enrichment of the gene set described for exhausted T cells (2) in TILN-derived tumor-specific T cells, relative to their blood-derived 
counterparts. The positions of inhibitory receptors found in this gene set on the rank-ordered gene list are indicated. A position to the left indicates 
enrichment in TILN-derived cells, a position to the right enrichment in blood-derived cells.
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peripheral blood (Figure 6C), confirming the results obtained by 
the microarray analysis. These data reveal a high level of heteroge-
neity, with multiple antigen-specific T cell subpopulations express-
ing different combinations of inhibitory receptors. It is likely that 
many of these subpopulations are effector memory cells and effec-
tor memory RA+, as they make up the vast majority of Melan-A– 
specific T cells (Supplemental Figure 3A). Naive and central mem-
ory cells were infrequent, but may nevertheless contribute to this 
heterogeneity. Furthermore, extended studies are necessary to 
determine the functional impact of coexpressed inhibitory recep-
tors. Finally, the marked differences between tumor-, CMV-, and 
EBV-specific T cells suggest different roles of inhibitory receptors 
in viral infection versus cancer.
Discussion
In peripheral blood, tumor-specific T cells induced by vaccination 
showed an effector cell profile (Supplemental Figure 5), similar 
to CMV-specific T cells and similar to the murine counterpart of 
CD8+ T cells in acute LCMV Armstrong infection (2). Differentia-
tion of EBV-specific CD8+ T cells was less pronounced, but they 
nevertheless resembled effector cells. In contrast to these 4 effector 
cell populations, tumor-specific T cells in situ displayed an exhaus-
tion profile, with significant similarity to murine T cells in chronic 
infection with LCMV clone 13 (2).
Tumor-infiltrating T cells are functionally deficient (20, 23, 
24, 34), which is likely coresponsible for the limited efficacy of 
immunotherapy. However, the underlying mechanisms remain 
poorly characterized, in contrast with chronic infectious diseases 
(1, 2). Our finding of T cell exhaustion in melanoma metastases 
results from what we believe is the first comprehensive molecu-
lar characterization of self- and tumor-specific T cells, providing 
explanations for their functional impairment. Tumor-specific T 
cells from metastases showed considerable molecular alterations, 
with surprisingly strong overexpression of many genes regulating 
various cell functions. This included genes involved in immune 
responses, cell death and apoptosis, and cell cycle and DNA repair. 
Thus, the data point to enhanced immune activation and apop-
tosis, and problems in maintaining DNA integrity and sustaining 
cell cycling in T cells of metastases.
We did not find significant correlations between our T cell data 
and clinical results (e.g., patient survival). However, phase I stud-
ies such as the present trial of immunotherapy are not suited for 
clinical outcome analysis. Rather, they are designed for provid-
ing enhanced biological insight. Indeed, we identified specific 
molecular alterations potentially representing molecular targets 
for improved therapy. Nevertheless, further studies are required 
to determine which of these targets are most promising for evalu-
ation in large-scale phase III clinical trials.
Based on the available evidence for functional T cell impairment 
in HIV-1, HBV, and HCV infections (11, 16–18, 37), it will be useful 
to perform comparative molecular profiling of T cells in different 
infections and malignancies in order to identify similarities and 
differences, providing the rational basis for therapy optimization. 
Very recently, HIV-1–specific T cells have been profiled, with iden-
tification of T cell exhaustion and BATF upregulation by PD-1 in 
patients failing to control HIV infection (18). Even though we did 
not find enhanced BATF expression in tumor-specific T cells from 
TILN, we observed similarities in gene expression signatures and 
upregulation of multiple inhibitory receptors on tumor-specific T 
cells also at the protein level.
Besides analysis of tumor-specific T cells after vaccination, 
it would be interesting to profile spontaneously arising T cell 
responses and naive tumor-specific T cells from patients and 
healthy donors, with the aim of identifying disease mechanisms 
responsible for altered T cell function. We expect that tumor-spe-
cific T cells from healthy donors would show an expression profile 
similar to total naive CD8+ T cells, while spontaneously responding 
T cells may show some degree of effector cell differentiation. How-
ever, such studies are technically challenging, since tumor-specific 
T cells in healthy donors and early stages of cancer are rare and 
difficult to isolate for ex vivo analysis. Therefore, laboratory tech-
niques must be optimized for comprehensive characterization of 
even smaller cell numbers, ultimately down to the single cell level.
T cell tolerance to self and tumor antigens is assured by nega-
tive selection in the thymus and through anergy induction and 
T cell deletion in the periphery. Anergy has been characterized in 
at least 9 different experimental settings, most of them in vitro 
models and/or CD4+ T cell models (26). Unfortunately, no com-
prehensive gene expression data are available. Therefore we could 
not systematically evaluate anergy in our study. Nevertheless, we 
made an attempt by evaluating 29 anergy-related genes described 
in a model of ionomycin-induced anergy and a model of deletional 
tolerance (38, 39). We found that some of these genes (e.g., CBLB 
and CTLA4) were enriched in tumor-specific T cells from metasta-
ses (Supplemental Table 4), but most of the described genes (e.g., 
ITCH, EGR2, and DGKZ) were not enriched (not shown).
Our study was performed in patients with advanced stage III–IV 
melanoma. It has been hypothesized that late cancer stages may 
be associated with T cell exhaustion (1), whereas anergy and tol-
erance would be induced already at early stages of tumorigenesis 
(40, 41). Possibly, self- and tumor-specific T cells may show dis-
crete alterations already at the naive stage and/or after spontane-
ous activation. Perhaps anergy mechanisms are functional even 
at later disease stages. The elucidation of these points requires 
further methodological progress. For the time being, our data 
support the conclusion that exhaustion likely contributes to the 
functional deficiencies, but does not rule out the involvement of 
further mechanisms such as anergy or self tolerance.
In circulating tumor-specific T cells, we found effector cell sig-
natures compatible with their ample production of granzyme B 
and perforin (Figure 4) and efficient expression of IFN-γ upon 
4-hour triggering with antigen (Supplemental Figure 3B and refs. 
20, 21). Due to the high efficacy of CpG 7909 as adjuvant, the 
circulating tumor-specific T cells studied here were more strongly 
Table 1
Expression of selected inhibitory receptors by tumor-specific 
T cells
	 	 From	TILN	 From	blood
	 Mean	 SD	 Mean	 SD
CTLA4 12.1 0.6 9.3 2.6
CD160 8.6 2.2 7.6 2.0
LAG3 11.5 1.2 10.8 0.9
2B4 8.3 1.2 7.7 1.0
PTGER4 9.5 1.8 9.0 3.1
KLRG1 6.5 1.3 8.7 1.7
Absolute expression values and SD of selected inhibitory receptors on 
a log2 scale.
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activated (19) than in most other cancer vaccine studies with their 
lower frequencies and less pronounced effector cell differentia-
tion. Thus, our data of circulating cells are not representative for 
the latter, but nevertheless demonstrate that self- and tumor-spe-
cific T cells have the potential to become effector cells. Despite 
the high efficacy of the adjuvant used, we could not observe sig-
nificant bystander effects on circulating T cells with specificities 
other than for the vaccine (Figure 1).
One could argue that vaccination should have activated the 
tumor-specific T cells to an even higher degree than CMV-specific 
T cells in healthy donors (which was actually the case in some of 
our melanoma patients; our unpublished observations). Protec-
tion from latent CMV is likely less demanding for T cells than 
protection from acute viral disease. Possibly, even more strongly 
activated T cells may be required for protection from cancer pro-
gression. Indeed, adoptive transfer therapy has shown that tumor-
specific T cells at much higher frequency and strong activation can 
eliminate large melanoma metastases (22). Molecular profiling 
of these cells in comparison with T cells during acute viral infec-
tions may reveal eventual differences from our data. Alternatively, 
therapeutic success and protection from disease may be primarily 
achieved due to high numbers of T cells with molecular proper-
ties similar to those described here. However, patients with acute 
viral infections are rarely accessible for clinicians and researchers. 
Moreover, antitumor vaccines rarely induce T cell responses com-
parable to acute viral infections. In contrast to vaccines consisting 
of synthetic molecules and inactivated pathogens, live vaccines 
(essentially vaccinia virus and yellow fever vaccine) can induce high 
T cell frequencies (42, 43) and efficient protection. Comprehensive 
profiling of these T cells is feasible and may likely contribute to 
identifying protective mechanisms of human T cells.
Differentiation from naive to effector T cells introduces large 
changes in expression of not only immune response genes, but also 
of genes involved in translation, in cell death and apoptosis, and 
in cell migration. These changes result in increased production of 
effector molecules, migration to pathologic tissue, and cell surviv-
al. Based on GO terms, we compared EBV- with circulating tumor-
specific T cells and found that the latter overexpressed genes 
involved in translation, cell death, and apoptosis, likely reflect-
ing the fact that the tumor-specific T cells were more advanced in 
Figure 6
Multi-tetramer staining assessing coexpression of inhibitory receptors. (A) Staining with tetramers binding to EBV- (PE–Texas Red), Melan-A/ 
MART-1– (APC–eFluor 780), or CMV- (PE–Texas Red and APC–eFluor 780) specific T cells (labeling tetramers with 2 instead of 1 fluorochrome 
identifies larger numbers of epitope-specific T cell populations than the number of fluorescence channels used). T cells were analyzed for coex-
pression of 7 inhibitory receptors: KLRG-1 (Alexa Fluor 488), TIM-3 (PE), PD-1 (PerCP-eFluor710), and CD160 (Alexa Fluor 647), or LAG-3 
(FITC), 2B4 (PE-Cy5.5), and CTLA-4 (APC). (B) Expression of 7 different inhibitory receptors. Histograms of a representative sample are gated on 
CD8+ tetramer+ cells. Box plots summarize the data of all patients analyzed (EBV, n = 16; CMV, n = 6; Melan-A blood, n = 10, except for CTLA-4, 
n = 3; Melan-A TILN, n = 8–9). Whiskers in box plots indicate the maximum and minimum values measured. Cross indicates the mean, while line 
indicates the median. *P < 0.05; #P < 0.01; §P < 0.001. (C) Coexpression of 0 to 4 and 0 to 3 inhibitory receptors was analyzed with SPICE (48).
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effector cell differentiation. Compared with CMV-specific T cells, 
circulating tumor-specific T cells expressed slightly more genes 
related to transcription, but fewer genes involved in cell migra-
tion. Despite these distinctions, the 3 effector cell populations 
from peripheral blood were relatively similar.
Inhibitory receptors were prominent among the differentially 
expressed genes. This group of genes is attracting increasing atten-
tion, also because of its importance in T cell exhaustion and thera-
peutic potential (2). Nevertheless, the circulating tumor-specific 
T cells expressed granzyme B and perforin at high levels and were 
functionally competent (19). Apparently, effector cells can express 
inhibitory receptors but nevertheless maintain functional compe-
tence. Our study demonstrates coexistence of functional cells in 
circulation and exhausted cells in metastases. We have preliminary 
data indicating that this may occur even within individual T cell 
clonotypes (our unpublished observations). It appears that migra-
tion of T cells into the tumor tissue is associated with downregula-
tion of cytokine production and exhaustion as a consequence of 
encountering inhibitory receptor ligands expressed in the tumor 
tissue, in conjunction with antigen recognition. Thus, exhaus-
tion of T cells in metastases but not in peripheral blood may be 
linked to the frequent and strong expression of these ligands in the 
tumor microenvironment. This interpretation is compatible with 
our earlier findings that the functional deficiency of tumor-resid-
ing T cells is readily reversible, since T cells from metastases regain 
function after 1 to 2 days culture in vitro (20, 44).
HCV-specific T cells may coexpress up to 4 of the inhibitory 
receptors KLRG1, 2B4, CD160, and PD-1, correlating with CD127 
downregulation and functional impairment (32). Even though 
many tumor-specific T cells expressed KLRG1, 2B4, PD-1, and 
TIM-3, they did not express CD160. This difference may be func-
tionally relevant for HCV- versus tumor-specific T cells. Moreover, 
expression of inhibitory receptors was more abundant in T cells 
from TILN as opposed to blood. The differential coexpression of 
multiple inhibitory receptors in viral infection versus cancer, and 
depending on antigen specificity/differentiation status and ana-
tomical localization, suggests that the functional regulation of 
antigen-specific T cells is more complex than previously thought.
In summary, our study provides comprehensive molecular pro-
files of human CD8+ T cells. Although tumor-specific T cells can 
acquire substantial effector cell properties, they display an exhaus-
tion profile in metastases. With modern technologies applied to 
small cell numbers, it becomes increasingly possible to determine 
whether functional impairment and molecular exhaustion of 
tumor-specific T cells are due to their specificity for self antigen, 
and/or immune suppression in situ.
Methods
Healthy donors, melanoma patients, lymphocyte isolation, and flow cytometry. 
Blood from 4 A2+ healthy donors was obtained from the university blood 
transfusion center of Lausanne, Switzerland. Peripheral blood and sur-
gery specimens were obtained from A*0201+ patients with stage III/IV 
metastatic melanoma. Patients had received multiple monthly low-dose 
vaccinations s.c. with 100 μg Melan-A/MART-1 peptide and CpG (500 μg 
PF-3512676/7909; provided by Pfizer/Coley Pharmaceutical Group), 
emulsified in IFA (300–600 μl Montanide ISA-51; provided by Seppic) as 
described previously (19). Analysis of circulating tumor-specific T cells was 
done after 11 ± 5 monthly vaccinations; the last was at a mean of 96 days 
before blood withdrawal. Tumor-specific T cells from TILN were prepared 
after finely mincing surgery specimens, which were obtained after 7 ± 2 
monthly vaccinations, the last at a mean of 79 days before surgery. Vaccina-
tions were done in the context of Ludwig Institute for Cancer Research tri-
als (19, 45) and approved by the Ludwig Institute for Cancer Research pro-
tocol review committee as well as by the medical and ethical committees of 
the University Hospital (Lausanne). Blood and tissue were obtained upon 
informed patient consent, and the study was performed according to the 
relevant regulatory standards. Mononuclear cells were purified by density 
gradient using Lymphoprep (Axis-Shield) and immediately cryopreserved 
in RPMI 1640 supplemented with 40% FCS and 10% DMSO.
For microarray analysis, 1,000 cells from each sample were sorted using a 
Vantage SE directly into lysis and storage buffer provided by Miltenyi Biotec 
as shown in Supplemental Figure 1. CD8+ T cells were enriched using mag-
netic bead sorting (Miltenyi Biotec). Cells were stained on ice and diluted 
at one million cells/ml. Cells were stained with CD8-specific antibody, 
the dead cell marker DAPI, and either with lineage markers (CD4, CD14, 
CD16, CD19) together with A2/EBV BMLF1280–288 (GLCTLVAML), A2/ 
CMV pp65495–503 (NLVPMVATV), or A2/Melan-A/MART-126–35A27L 
(ELAGIGILTV) tetramers binding to high- and low-affinity T cell recep-
tors (46) or with CD45RA-, CCR7-, CD28-, and CD27-specific antibod-
ies. Naive T cells were defined as CD8+CD45RA+CCR7+CD27+CD28+. The 
sorting strategy is shown in Supplemental Figure 1. Manipulations were 
done at 4°C, avoiding gene expression alteration due to staining and sort-
ing. Sorting purity was high, as determined by analyzing aliquots before 
and after FACS sorting. Representative examples are shown in Supplemen-
tal Figure 1, B–D. Among CD8+ T cells, percentages for A2/EBV tetramer+ 
cells were 1.00 ± 0.89 (4 healthy donors and 12 patients); for A2/CMV 
tetramer+ cells, 1.53 ± 1.08 (7 patients); and for A2/Melan-A/MART-1 tet-
ramer+ cells, 1.43 ± 1.31 in blood (11 patients) and 3.35 ± 3.35 in TILN 
(7 patients). After sorting, lysed cells were incubated for 10 minutes at 
45°C and then directly frozen at –80°C.
Intracellular antibody staining was performed as previously described 
(27). In brief, cells from the CD8+ fraction were first stained with PE-labeled 
tetramers, followed by anti–CD8–Pacific Blue antibody. After washing in 
PBS, cells were incubated with LIVE/DEAD-Fixable-Aqua (Invitrogen) for 
dead cell exclusion, and fixed at room temperature (RT) during 30 min-
utes (1% formaldehyde buffer). Cells were washed and stained with mAbs 
anti–perforin-FITC or anti–granzyme B–FITC (BD) in FACS buffer with 
0.1% saponin for 30 minutes at 4°C. For the staining of IFN-γ, CD8+ cells 
were stimulated with peptide-loaded T2 cells for 4 hours in the presence of 
Brefeldin-A (Sigma-Aldrich) prior to antibody staining with anti–IFN-γ– 
PE-Cy7 (BD Pharmingen). Data of IFN-γ–production from tumor-specific 
T cells were previously published (20).
For antibody staining of multiple inhibitory receptors, samples were 
purified and enriched as described above and then stained using tetramers 
detecting the same EBV, CMV, or Melan-A/MART-1 epitopes as described 
above. Melan-A–specific tetramers were labeled with APC–eFluor 780 
(eBioscience), EBV-specific tetramers were labeled with PE–Texas Red 
(BD Pharmingen), and CMV-specific tetramers were labeled with both 
APC–eFluor 780 and PE–Texas Red, allowing for individual analysis of T 
cells specific for the 3 epitopes in a single sample (multi-tetramer staining 
technique; ref. 47). After 45 minutes at 4°C, cells were washed and surface 
staining was performed for CD8, CCR7, CD45RA and (a) LAG-3 (Alexis 
Biochemicals) and 2B4 (BioLegend) or (b) KLRG-1 (gift from H.-P. Pircher, 
Department of Immunology, University of Freiburg, Freiburg, Germany), 
TIM-3 (R&D Systems), PD-1 (eBioscience), and CD160 (eBioscience). 
Samples (a) were fixed at room temperature for 30 minutes (1% formalde-
hyde buffer) and then stained for CTLA-4 (BD Biosciences — Pharmingen) 
in FACS buffer with 0.1% saponin for 30 minutes at 4°C. LIVE/DEAD-
Fixable-Aqua (Invitrogen) was used as a dead cell exclusion marker, and 
appropriate isotype controls were used to define negative populations. 
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Data were acquired on a Gallios Flow Cytometer (Beckman Coulter) and 
analyzed using FlowJo 9.1 (TreeStar). Analysis of coexpression of inhibi-
tory receptors used SPICE version 5.1 (48).
Microarray and qPCR. Gene expression profiling was done in 2 experi-
ments. The first experiment included samples from blood-derived naive, 
EBV-, and tumor-specific T cells. The second experiment included tumor-
specific T cells from blood and metastasis, and CMV-specific T cells from 
blood. Frozen samples were sent to Miltenyi Biotec and processed according 
to the vendor-recommended protocol for gene expression analysis. Sam-
ples were hybridized to Agilent Whole Human Genome Oligo Microarrays 
4x44K and scanned using the Agilent microarray scanner system (Agilent). 
The Agilent Feature Extraction Software was used for readout and process-
ing of image files. Background correction, filtering of data, and quantile 
normalization were done using the Agi4x44PreProcess software package as 
described in the package manual. The Limma software package was used 
to identify the differentially expressed genes and creation of rank-ordered 
lists. We analyzed eventual contaminations from B cells, monocytes, and 
dendritic cells, and found that expression levels of IGHG1, CD19, TLRs, 
and CD1 were between 0.28% and 2.72% of the respective expression of 
CD3E, confirming the high purity of our samples. We also evaluated intra-
group variability possibly leading to high background. For this, we ran-
domly split the data from 13 naive CD8+ T cell samples into 3 pairs of 
2 groups of 6 and 7 samples each and analyzed differences between the 
groups. We found that none of the gene probes were different in any of the 
pairings, demonstrating that the background was low (data not shown). 
For nonnaive cells (Figure 2), the data from EBV- and tumor-specific CD8+ 
T cells were pooled. Genes were assigned to broad GO terms using the GO 
Term Mapper (http://go.princeton.edu/cgi-bin/GOTermMapper), yield-
ing both the percentage of submitted genes attributed to a given GO term 
versus the percentage of all annotated genes attributed to that GO term. 
Relative overrepresentation was calculated by dividing the percentage of 
submitted genes attributed to a GO term by the percentage of all avail-
able genes annotated with this GO term. Rank-ordered gene lists (ranked 
according to the B value) were analyzed with GSEA (www.broadinstitute.
org/gsea; ref. 49). Enrichment was considered significant if P was less than 
0.05 and FDR was less than 0.25 as suggested in the online tool.
qPCR was performed to validate the enriched genes observed in microarray 
experiments. Custom-ordered oligos (Microsynth) were designed using the 
online tool from Universal Roche Library Assay Design Centre (Supplemen-
tal Table 5). Reaction mix used was Power Sybr Green Master Mix (Applied 
Biosystems), and amplification was monitored with Applied Biosystems 
7900HT Fast Real-Time PCR System (15-minute enzyme activation and 
40 cycles of 15 seconds 95°C, 1 minute 60°C). A Hamilton Liquid Handling 
Robotic System was used to assemble the 384-well plates. Amplified cDNA 
samples used for microarray analysis were diluted (1:50) and used for qPCR 
after confirming the linear and single product amplification by the primers. 
Samples were measured in triplicate. GAPDH was used as a housekeeping 
gene to calculate relative expression values.
Statistics. For quantitative comparisons, Student’s t test (2-sample 2-tailed 
comparison) or 1-way ANOVA with Tukey post-test (multiple-sample com-
parison) was performed with Prism 5.0; P < 0.05 was considered as signifi-
cant. P values and FDRs for GSEA were calculated with 1,000 permutations 
in the online tool. Microarray analysis was done with relatively restrictive 
criteria, i.e., by considering gene probes as significant if the P value, cor-
rected for a FDR of 0.05, was P ≤ 0.05 and the fold change was ≥ 3.
Accession numbers. The gene-expression data described in this paper have 
been deposited in the NCBI Gene Expression Omnibus and are accessible 
through the GEO accession number GSE24536.
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